Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- BB +9.5%, APOG +8%, TH +7.3% (guidance), FUL +5%, WS +4.3%, CNXC +3.4%, FC +3.3%, MKC +2.8%, SMPL +1.1%
Other news:
- VIGL +36.2% (announces $40 million strategic investment from Sanofi)
- IIIV +20.5% (to sell merchant of record payments business for $440 mln in cash)
- ATEX +14.4% (Oncor Electric to acquire 900 MHz broadband spectrum from ATEX; ATEX also reports earnings)
- VRNA +6.4% (FDA approves Ohtuvayre)
- NVX +6.3% (granted patent for all-dry, zero-waste cathode synthesis)
- ELEV +5.1% (Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer)
- GLUE +4.9% (Provides development progress updates on MRT-2359 and MRT-6160)
- XFOR +4% (interim clinical data from ongoing six-month phase 2 trial of mavorixafor in chronic neutropenia and initiation of pivotal phase 3 CN trial)
- TSVT +3.9% (TSVT sells certain gene editing technology to NVO for $40 mln)
- RH +3.6% (Chairman & CEO Gary Friedman completed the purchase of $10 million of RH stock at an average price per share of $216.10 representing 46,274 shares) GROY +2.9% (stock offering by selling shareholder)
- VIV +2.7% (approved the proposed terms and conditions for the Self-Composition Agreement for Adaptation of the STFC Concession Contracts to an Authorization instrument)
- SLN +1.9% (Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients)
- NOK +1.6% (enters into an agreement with the French State regarding the sale of leading submarine networks business ASN)
- TXO +1.2% (prices offering 6.5 mln common units at $20.00 per share)
- MARA +1% (announces Kaspa mining ops)
- E +0.9% (agrees to sell upstream assets in Alaska)